ABT
Abbott Laboratories NYSE Listed Mar 17, 1980$86.99
Mkt Cap $151.5B
52w Low $86.15
1.6% of range
52w High $139.06
50d MA $102.44
200d MA $120.01
P/E (TTM)
23.9x
EV/EBITDA
19.5x
P/B
3.0x
Debt/Equity
0.3x
ROE
12.1%
P/FCF
29.6x
RSI (14)
—
ATR (14)
—
Beta
0.78
50d MA
$102.44
200d MA
$120.01
Avg Volume
11.7M
Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The Established Pharmaceutical Products segment provides generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, Ménière's disease and vestibular vertigo, pain, fever, inflammation, and migraine, as well as provides anti-infective clarithromycin, influenza vaccine, and products to regulate physiological rhythm of the colon. The Diagnostic Products segment offers laboratory systems in the areas of immunoassay, clinical chemistry, hematology, and transfusion; molecular diagnostics systems that automate the extraction, purification, and preparation of DNA and RNA from patient samples, as well as detect and measure infectious agents; point of care systems; cartridges for testing blood; rapid diagnostics lateral flow testing products; molecular point-of-care testing for HIV, SARS-CoV-2, influenza A and B, RSV, and strep A; cardiometabolic test systems; drug and alcohol test, and remote patient monitoring and consumer self-test systems; and informatics and automation solutions for use in laboratories. The Nutritional Products segment provides pediatric and adult nutritional products. The Medical Devices segment offers rhythm management, electrophysiology, heart failure, vascular, and structural heart devices for the treatment of cardiovascular diseases; and diabetes care products, as well as neuromodulation devices for the management of chronic pain and movement disorders. Abbott Laboratories was founded in 1888 and is based in North Chicago, Illinois.
100 Abbott Park Road · Abbott Park, IL 60064-6400 · US
| Date | Time | Est | Rptd | Surp | Base | Gap% | D1% | D2% | D3% | D4% | D5% | Guide ▲★ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Apr 16, 2026 | AMC | 1.14 | 1.15 | +0.9% | 95.47 | +0.2% | +1.4% | -0.8% | -3.4% | -1.1% | +0.9% | — |
| Jan 22, 2026 | AMC | 1.50 | 1.50 | +0.0% | 108.61 | -0.3% | -1.1% | +1.3% | -0.5% | -2.1% | +0.0% | — |
| Oct 15, 2025 | AMC | 1.30 | 1.30 | +0.0% | 129.45 | +0.1% | -1.4% | +0.7% | +0.8% | -1.5% | +0.3% | — |
| Jul 17, 2025 | AMC | 1.26 | 1.26 | +0.0% | 120.51 | +1.8% | +2.6% | +0.6% | +1.1% | +0.1% | -0.2% | — |
| Apr 16, 2025 | AMC | 1.07 | 1.09 | +1.9% | 129.70 | +0.5% | +1.0% | -0.8% | +1.4% | -1.4% | -0.4% | — |
| Jan 22, 2025 | AMC | 1.34 | 1.34 | +0.0% | 117.78 | +0.3% | +4.6% | +1.5% | +3.5% | -1.6% | +0.4% | — |
| Oct 16, 2024 | AMC | 1.20 | 1.21 | +0.8% | 117.82 | +0.8% | +0.1% | +1.3% | -2.0% | -0.7% | +0.8% | — |
| Jul 18, 2024 | AMC | 1.10 | 1.14 | +3.6% | 100.07 | +0.5% | +2.0% | +1.7% | +0.2% | +3.2% | -1.2% | — |
| Apr 17, 2024 | AMC | 0.95 | 0.98 | +2.6% | 105.90 | +0.6% | -0.6% | +1.9% | -0.2% | +0.5% | -0.7% | — |
| Jan 24, 2024 | AMC | 1.19 | 1.19 | +0.0% | 110.77 | +0.6% | +1.5% | -0.4% | +1.3% | +0.0% | -0.3% | — |
| Oct 18, 2023 | AMC | 1.10 | 1.14 | +3.6% | 95.56 | +1.0% | -0.1% | +1.4% | -1.0% | -1.0% | -1.3% | — |
| Jul 20, 2023 | AMC | 1.04 | 1.08 | +3.8% | 111.83 | +0.9% | +2.2% | +0.3% | -1.5% | +1.0% | -1.3% | — |
| Date | Firm | Action | Grade | Target | Base | Open | Gap% | D1% | D2% | D3% | D4% | D5% |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Apr 27 | BTIG | Maintains | Buy → Buy | — | $91.13 | $91.62 | +0.5% | +1.8% | +1.1% | -2.7% | -0.6% | -1.5% |
| Apr 22 | Daiwa Securities | Downgrade | Outperform → Neutral | $92 | $92.72 | $92.62 | -0.1% | -1.1% | +0.9% | -1.5% | +1.8% | +1.1% |
| Apr 20 | Barclays | Maintains | Overweight → Overweight | — | $96.81 | $96.50 | -0.3% | -0.8% | -3.4% | -1.1% | +0.9% | -1.5% |
| Apr 17 | RBC Capital | Maintains | Outperform → Outperform | — | $95.47 | $95.62 | +0.2% | +1.4% | -0.8% | -3.4% | -1.1% | +0.9% |
| Apr 17 | BTIG | Maintains | Buy → Buy | — | $95.47 | $95.62 | +0.2% | +1.4% | -0.8% | -3.4% | -1.1% | +0.9% |
| Apr 17 | Stifel | Maintains | Buy → Buy | — | $95.47 | $95.62 | +0.2% | +1.4% | -0.8% | -3.4% | -1.1% | +0.9% |
| Apr 17 | Oppenheimer | Maintains | Outperform → Outperform | — | $95.47 | $95.62 | +0.2% | +1.4% | -0.8% | -3.4% | -1.1% | +0.9% |
| Apr 17 | Piper Sandler | Maintains | Overweight → Overweight | — | $95.47 | $95.62 | +0.2% | +1.4% | -0.8% | -3.4% | -1.1% | +0.9% |
| Apr 17 | Benchmark | Maintains | Buy → Buy | — | $95.47 | $95.62 | +0.2% | +1.4% | -0.8% | -3.4% | -1.1% | +0.9% |
| Apr 17 | Evercore ISI | Maintains | Outperform → Outperform | — | $95.47 | $95.62 | +0.2% | +1.4% | -0.8% | -3.4% | -1.1% | +0.9% |
| Apr 17 | BofA Securities | Maintains | Buy → Buy | — | $95.47 | $95.62 | +0.2% | +1.4% | -0.8% | -3.4% | -1.1% | +0.9% |
| Apr 9 | Goldman Sachs | Maintains | Buy → Buy | — | $103.56 | $103.00 | -0.5% | -0.8% | -2.4% | +0.4% | +0.4% | +0.5% |
| Apr 8 | Barclays | Maintains | Overweight → Overweight | — | $101.83 | $103.13 | +1.3% | +1.7% | -0.8% | -2.4% | +0.4% | +0.4% |
| Apr 6 | Evercore ISI | Maintains | Outperform → Outperform | — | $102.87 | $102.51 | -0.3% | -0.6% | -0.5% | +1.7% | -0.8% | -2.4% |
| Mar 31 | BTIG | Maintains | Buy → Buy | — | $101.88 | $102.54 | +0.6% | +0.8% | -0.3% | +0.5% | -0.6% | -0.5% |
| Mar 26 | Piper Sandler | Maintains | Overweight → Overweight | — | $104.83 | $104.39 | -0.4% | -0.2% | -0.6% | -2.0% | +0.8% | -0.3% |
| Mar 11 | Citigroup | Maintains | Buy → Buy | — | $110.55 | $110.00 | -0.5% | -0.3% | -1.9% | -0.1% | +1.8% | +0.7% |
| Feb 2 | Barclays | Maintains | Overweight → Overweight | — | $109.30 | $109.23 | -0.1% | +0.1% | -0.4% | -0.8% | +0.8% | +1.6% |
| Jan 29 | Freedom Broker | Upgrade | Hold → Buy | — | $106.05 | $106.44 | +0.4% | +0.0% | +3.0% | +0.1% | -0.4% | -0.8% |
| Jan 23 | Piper Sandler | Maintains | Overweight → Overweight | — | $108.61 | $108.27 | -0.3% | -1.1% | +1.3% | -0.5% | -2.1% | +0.0% |
| Jan 23 | Bernstein | Maintains | Outperform → Outperform | — | $108.61 | $108.27 | -0.3% | -1.1% | +1.3% | -0.5% | -2.1% | +0.0% |
| Jan 23 | Evercore ISI | Maintains | Outperform → Outperform | — | $108.61 | $108.27 | -0.3% | -1.1% | +1.3% | -0.5% | -2.1% | +0.0% |
| Jan 23 | Oppenheimer | Maintains | Outperform → Outperform | — | $108.61 | $108.27 | -0.3% | -1.1% | +1.3% | -0.5% | -2.1% | +0.0% |
| Jan 23 | RBC Capital | Maintains | Outperform → Outperform | — | $108.61 | $108.27 | -0.3% | -1.1% | +1.3% | -0.5% | -2.1% | +0.0% |
| Jan 23 | BTIG | Maintains | Buy → Buy | — | $108.61 | $108.27 | -0.3% | -1.1% | +1.3% | -0.5% | -2.1% | +0.0% |
| Jan 23 | Citigroup | Maintains | Buy → Buy | — | $108.61 | $108.27 | -0.3% | -1.1% | +1.3% | -0.5% | -2.1% | +0.0% |
| Jan 9 | Bernstein | Maintains | Outperform → Outperform | — | $126.18 | $126.42 | +0.2% | -0.2% | -1.0% | -0.3% | +0.6% | -1.2% |
| Jan 5 | Barclays | Maintains | Overweight → Overweight | — | $124.19 | $123.63 | -0.5% | +1.8% | +1.1% | -0.6% | -0.7% | -0.2% |
| Nov 20 | BTIG | Maintains | Buy → Buy | — | $126.15 | $122.50 | -2.9% | -1.7% | +3.3% | -0.7% | +0.7% | +0.4% |
| Oct 17 | Barclays | Maintains | Overweight → Overweight | — | $127.63 | $127.86 | +0.2% | +0.7% | +0.8% | -1.5% | +0.3% | -1.3% |
| Oct 16 | Raymond James | Maintains | Outperform → Outperform | — | $129.45 | $129.53 | +0.1% | -1.4% | +0.7% | +0.8% | -1.5% | +0.3% |
| Oct 16 | Wells Fargo | Maintains | Overweight → Overweight | — | $129.45 | $129.53 | +0.1% | -1.4% | +0.7% | +0.8% | -1.5% | +0.3% |
| Oct 16 | Evercore ISI | Maintains | Outperform → Outperform | — | $129.45 | $129.53 | +0.1% | -1.4% | +0.7% | +0.8% | -1.5% | +0.3% |
| Oct 16 | RBC Capital | Maintains | Outperform → Outperform | — | $129.45 | $129.53 | +0.1% | -1.4% | +0.7% | +0.8% | -1.5% | +0.3% |
| Oct 15 | BTIG | Maintains | Buy → Buy | — | $133.27 | $128.01 | -3.9% | -2.9% | -1.4% | +0.7% | +0.8% | -1.5% |
| Oct 7 | Evercore ISI | Maintains | Outperform → Outperform | — | $133.74 | $134.09 | +0.3% | -0.5% | +0.9% | -0.7% | -0.6% | -0.9% |
| Sep 10 | Bernstein | Maintains | Outperform → Outperform | — | $131.95 | $131.85 | -0.1% | -2.0% | +2.5% | +0.8% | -1.8% | +1.1% |
| Jul 18 | BTIG | Maintains | Buy → Buy | — | $120.51 | $122.63 | +1.8% | +2.6% | +0.6% | +1.1% | +0.1% | -0.2% |
| Jul 18 | Raymond James | Maintains | Outperform → Outperform | — | $120.51 | $122.63 | +1.8% | +2.6% | +0.6% | +1.1% | +0.1% | -0.2% |
| Jul 18 | Jefferies | Upgrade | Hold → Buy | — | $120.51 | $122.63 | +1.8% | +2.6% | +0.6% | +1.1% | +0.1% | -0.2% |
| Jul 18 | Citigroup | Maintains | Buy → Buy | — | $120.51 | $122.63 | +1.8% | +2.6% | +0.6% | +1.1% | +0.1% | -0.2% |
| Jul 18 | Wells Fargo | Maintains | Overweight → Overweight | — | $120.51 | $122.63 | +1.8% | +2.6% | +0.6% | +1.1% | +0.1% | -0.2% |
| Jul 18 | Mizuho | Maintains | Neutral → Neutral | — | $120.51 | $122.63 | +1.8% | +2.6% | +0.6% | +1.1% | +0.1% | -0.2% |
| Jul 17 | Evercore ISI | Maintains | Outperform → Outperform | — | $131.74 | $126.55 | -3.9% | -8.5% | +2.6% | +0.6% | +1.1% | +0.1% |
| Jul 16 | Mizuho | Maintains | Neutral → Neutral | — | $131.49 | $132.12 | +0.5% | +0.2% | -8.5% | +2.6% | +0.6% | +1.1% |
| Jul 15 | Morgan Stanley | Maintains | Equal Weight → Equal Weight | — | $132.03 | $131.90 | -0.1% | -0.4% | +0.2% | -8.5% | +2.6% | +0.6% |
| Jul 15 | RBC Capital | Maintains | Outperform → Outperform | — | $132.03 | $131.90 | -0.1% | -0.4% | +0.2% | -8.5% | +2.6% | +0.6% |
| Jul 14 | BTIG | Maintains | Buy → Buy | — | $132.02 | $132.02 | +0.0% | +0.0% | -0.4% | +0.2% | -8.5% | +2.6% |
| Jul 9 | Citigroup | Maintains | Buy → Buy | — | $133.36 | $133.47 | +0.1% | -0.1% | +0.3% | -1.2% | +0.0% | -0.4% |
| Jul 8 | Evercore ISI | Maintains | Outperform → Outperform | — | $133.70 | $133.24 | -0.3% | -0.3% | -0.1% | +0.3% | -1.2% | +0.0% |
| Date | Insider | Title | Type | Shares | Price | Value | Owned After | D1% | D5% |
|---|---|---|---|---|---|---|---|---|---|
| Apr 27, 2026 | STARKS DANIEL J | — | Buy | 10,000 | $92.65 | $927K | 6,751,103 | -2.70% | -0.15% |
| Apr 23, 2026 | Boudreau Philip P | EVP AND CFO | Buy | 2,200 | $91.50 | $201K | 2,200 | +1.14% | -2.15% |
8-K · 5.02
!!! Very High
Abbott Laboratories -- 8-K 5.02: Executive Change
Apr 27
8-K · 8.01
!! High
Abbott Laboratories -- 8-K 8.01: Material Event / Announcement
Abbott settled six shareholder derivative lawsuits related to its infant formula crisis for an undisclosed amount, with the settlement requiring court approval and potentially affecting director and officer liability exposure.
Apr 17
8-K
Unknown — 8-K Filing
Abbott is reminding investors that management relies on non-GAAP metrics internally, but GAAP results should remain primary—suggesting actual reported earnings may look weaker than management's preferred performance measures.
Apr 16
8-K · 5.02
!!! Very High
Unknown — 8-K 5.02: Executive Change
The departure of an executive effective April 15, 2026 signals potential leadership uncertainty; investors should monitor whether the replacement demonstrates strategic continuity or signals broader organizational concerns affecting these companies' performance.
Apr 14
8-K · 5.02
!!! Very High
Unknown — 8-K 5.02: Executive Change
Abbott's failure to promote Teplitsky to COO signals internal management instability and potential leadership challenges, which could concern investors about strategic direction and executive bench strength.
Apr 9
8-K · 2.01
!!! Very High
Unknown — 8-K 2.01: Acquisition Completed
Abbott has completed a significant acquisition, likely expanding its product portfolio and market reach, which could drive revenue growth and shareholder value if the target company's assets integrate successfully.
Mar 23
8-K · 8.01
!! High
Unknown — 8-K 8.01: Material Event / Announcement
Abbott Laboratories announced a significant transaction with Exact Sciences Corporation on March 23, 2026, potentially indicating a major acquisition or partnership that could reshape its diagnostic business and impact future growth prospects.
Mar 23
8-K
Unknown — 8-K Filing
Abbott's acquisition of Exact Sciences faces material business risks that could impact integration success and profitability, warranting investor scrutiny of synergy realization and operational challenges ahead.
Mar 20
8-K · 5.02
!!! Very High
Unknown — 8-K 5.02: Executive Change
Abbott Laboratories' appointment of a new executive effective April 1, 2026, signals potential strategic shifts in operations or leadership direction that could affect near-term stock performance and investor confidence in company management.
Mar 18
8-K · 1.01
! Medium
Abbott Laboratories -- 8-K 1.01: Financing / Debt Agreement
Abbott Laboratories issued debt notes through underwriters Morgan Stanley, Barclays, and BofA Securities, expanding its financing capacity for future operations and strategic investments.
Mar 9
8-K · 1.01
!! High
Abbott Laboratories -- 8-K 1.01: Material Agreement
Abbott Laboratories entered into a pricing agreement with Morgan Stanley, Barclays Capital, and BofA Securities, likely for a debt or equity offering, establishing standard contractual protections for the underwriting transaction.
Feb 26
8-K
EXACT SCIENCES CORP -- 8-K Filing
Exact Sciences shareholders approved the company's acquisition by Abbott Laboratories, clearing the final regulatory and shareholder hurdle for the deal to close.
Feb 20
8-K · 5.03
! Medium
Abbott Laboratories -- 8-K 5.03: Amendment to Articles / Bylaws
Abbott Laboratories changed its fiscal year-end, which may affect future earnings report timing and investor planning for financial statement releases.
Feb 20
8-K
EXACT SCIENCES CORP -- 8-K Filing
Abbott faces lawsuit allegations of violating New York and Wisconsin securities laws in connection with its acquisition of Exact Sciences, potentially creating legal and financial risks for both companies.
Feb 10
Data updated apr 24, 2026 10:18am
· Source: massive.com